Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease

Nephrology Dialysis Transplantation

Volumn 27, Issue 3, 2012, Pages 906-912

  Lian, Michael ^a   Hewitson, Tim D ^a   Wigg, Belinda ^a   Samuel, Chrishan S ^a   Chow, Fiona ^a   Becker, Gavin J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Albuminuria; Aldosterone; Diabetic nephropathy; Fibrosis

Indexed keywords

ALDOSTERONE RECEPTOR; COLLAGEN TYPE 4; CYCLINE; EPLERENONE; GLUCOSE; MINERALOCORTICOID RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ALBUMINURIA; ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD PRESSURE MEASUREMENT; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; KIDNEY HYPERTROPHY; KIDNEY MASS; KIDNEY SIZE; LONG TERM CARE; MACROPHAGE MIGRATION; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; SPONTANEOUSLY HYPERTENSIVE RAT; WESTERN BLOTTING;

ALDOSTERONE; ANIMALS; BLOOD PRESSURE; BLOTTING, WESTERN; COLLAGEN TYPE IV; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HYPERGLYCEMIA; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RATS; RATS, INBRED SHR; SPIRONOLACTONE; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84860531024     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr495     Document Type: Article

References (37)

1. Friedman AL, Friedman EA, Eggers P. End-stage renal disease in diabetic persons: Is the pandemic subsiding? Kidney Int 2006; 70: 51-54
2. Becker GJ, Hewitson TD, Chrysostomou A. Aldosterone in clinical nephrology-old hormone, new questions. Nephrol Dial Transplant 2009; 24: 2316-2321
3. Remuzzi G, Cattaneo D, Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. J AmSoc Nephrol 2008; 19: 1459-1462
4. Rossing K, Schjoedt KJ, Smidt UM et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005; 28: 2106-2112
5. Saklayen MG, Gyebi LK, Tasosa J et al. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. J Investig Med 2008; 56: 714-719
6. Sato A, Hayashi K, NaruseMet al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68
7. Schjoedt KJ, Rossing K, Juhl TR et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70: 536-542
8. van den Meiracker AH, Baggen RG, Pauli S et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens 2006; 24: 2285-2292
9. Fujisawa G, Okada K, Muto S et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 2004; 66: 1493-1502
10. Karagiannis A, Tziomalos K, Papageorgiou A et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother 2008; 9: 509-515
11. Cooper ME, Rumble JR, Allen TJ et al. Antihypertensive therapy in a model combining spontaneous hypertension with diabetes. Kidney Int 1992; 41: 898-903
12. Liang YH, Wang JM, Zhou Y et al. Additive effects of combined valsartan and spironolactone on cardiac aldosterone escape in spontaneously hypertensive rats. Life Sci 2004; 75: 1871-1878
13. Kang YM, Zhang ZH, Johnson RF et al. Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure. Circ Res 2006; 99: 758-766
14. Hewitson TD, Mookerjee I, Masterson R et al. Endogenous relaxin is a naturally occurring modulator of experimental renal tubulointerstitial fibrosis. Endocrinology 2007; 148: 660-669
15. Mifsud SA, Skinner SL, Cooper ME et al. Effects of low-dose and early versus late perindopril treatment on the progression of severe diabetic nephropathy in (mREN-2)27 rats. J Am Soc Nephrol 2002; 13: 684-692
16. Hewitson TD, Darby IA, Bisucci T et al. Evolution of tubulointerstitial fibrosis in experimental renal infection and scarring. J Am Soc Nephrol 1998; 9: 632-642
17. Lyons RM, Gentry LE, Purchio AF et al. Mechanism of activation of latent transforming growth factor beta1 by plasmin. J Cell Biol 1990; 110: 1361-1367
18. Maruyama M, Sugiyama H, Sada K et al. Desmin as a marker of proteinuria in early stages of membranous nephropathy in elderly patients. Clin Nephrol 2007; 68: 73-80
19. Gross JL, de Azevedo MJ, Silveiro SP et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005; 28: 164-176
20. McDonald S, Excell L, Livingston B. 32nd ANZDATA Registry Report 2010, Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia
21. Bell DS. Treatment of heart failure in patients with diabetes: clinical update. Ethn Dis 2002; 12: S1-S8
22. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensinconverting- enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 977-986
23. Asai M, Monkawa T, Marumo T et al. Spironolactone in combination with cilazaprilameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis. Hypertens Res 2004; 27: 971-978
24. Kramer AB, van der Meulen EF, Hamming I et al. Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis. Kidney Int 2007; 71: 417-424
25. Shibata S, Nagase M, Yoshida S et al. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007; 49: 355-364
26. Miric G, Dallemagne C, Endre Z et al. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 2001; 133: 687-694
27. Wuthrich RP, Glimcher LH, Yui MA et al. MHC class II, antigen presentation and tumor necrosis factor in renal tubular epithelial cells. Kidney Int 1990; 37: 783-792
28. Kang YS, Ko GJ, Lee MH et al. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Nephrol Dial Transplant 2009; 24: 73-84
29. Nelson RG, Tuttle KR. Prevention of diabetic kidney disease: negative clinical trials with renin-angiotensin system inhibitors. Am J Kidney Dis 2010; 55: 426-430
30. Susic D, Varagic J, Ahn J et al. Long-term mineralocorticoid receptor blockade reduces fibrosis and improves cardiac performance and coronary hemodynamics in elderly SHR. Am J Physiol Heart Circ Physiol 2007; 292: H175-H179
31. Arima S, Kohagura K, Xu HL et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003; 14: 2255-2263
32. Nishiyama A, Yao L, Fan Y et al. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 2005; 45: 710-716
33. Nagai Y, Miyata K, Sun GP et al. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 2005; 46: 1039-1045
34. Guo C, Martinez-Vasquez D, Mendez GP et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 2006; 147: 5363-5373
35. Nishiyama A, Yao L, Nagai Y et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 2004; 43: 841-848
36. Liu G, Miyata K, Hitomi H et al. Involvement of mineralocorticoid receptor in high glucose-induced big mitogen-activated protein kinase 1 activation and mesangial cell proliferation. J Hypertens 2010; 28: 536-542
37. Yuan J, Jia R, Bao Y. Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats. J Renin Angiotensin Aldosterone Syst 2007; 8: 118-126